Department of Pediatrics, Case Western Reserve University, Cleveland, Ohio, United States.
Department of Biochemistry and Molecular Genetics, University of Illinois at Chicago, Chicago, Illinois, United States.
Am J Physiol Lung Cell Mol Physiol. 2024 Mar 1;326(3):L377-L392. doi: 10.1152/ajplung.00269.2023. Epub 2024 Jan 30.
Sphingosine kinase 1 (SPHK1) has been shown to play a key role in the pathogenesis of asthma where SPHK1-generated sphingosine-1-phosphate (S1P) is known to mediate innate and adaptive immunity while promoting mast cell degranulation. Goblet cell metaplasia (GCM) contributes to airway obstruction in asthma and has been demonstrated in animal models. We investigated the role of PF543, a SPHK1-specific inhibitor, in preventing the pathogenesis of GCM using a murine (C57BL/6) model of allergen-induced acute asthma. Treatment with PF543 before triple allergen exposure (DRA: House dust mite, Ragweed pollen, and Aspergillus) reduced inflammation, eosinophilic response, and GCM followed by reduced airway hyperreactivity to intravenous methacholine. Furthermore, DRA exposure was associated with increased expression of SPHK1 in the airway epithelium which was reduced by PF543. DRA-induced reduction of acetylated α-tubulin in airway epithelium was associated with an increased expression of NOTCH2 and SPDEF which was prevented by PF543. In vitro studies using human primary airway epithelial cells showed that inhibition of SPHK1 using PF543 prevented an allergen-induced increase of both NOTCH2 and SPDEF. siRNA silencing of SPHK1 prevented the allergen-induced increase of both NOTCH2 and SPDEF. NOTCH2 silencing was associated with a reduction of SPDEF but not that of SPHK1 upon allergen exposure. Our studies demonstrate that inhibition of SPHK1 protected allergen-challenged airways by preventing GCM and airway hyperreactivity, associated with downregulation of the NOTCH2-SPDEF signaling pathway. This suggests a potential novel link between SPHK1, GCM, and airway remodeling in asthma. The role of SPHK1-specific inhibitor, PF543, in preventing goblet cell metaplasia (GCM) and airway hyperreactivity (AHR) is established in an allergen-induced mouse model. This protection was associated with the downregulation of NOTCH2-SPDEF signaling pathway, suggesting a novel link between SPHK1, GCM, and AHR.
鞘氨醇激酶 1(SPHK1)已被证明在哮喘发病机制中发挥关键作用,其中 SPHK1 产生的鞘氨醇-1-磷酸(S1P)已知可介导先天和适应性免疫,同时促进肥大细胞脱颗粒。杯状细胞化生(GCM)导致哮喘中的气道阻塞,并已在动物模型中得到证实。我们使用过敏原诱导的急性哮喘小鼠(C57BL/6)模型研究了 SPHK1 特异性抑制剂 PF543 预防 GCM 发病机制的作用。在三重过敏原暴露(DRA:尘螨、豚草花粉和曲霉)之前用 PF543 治疗可减少炎症、嗜酸性粒细胞反应和 GCM,随后减少对静脉内乙酰甲胆碱的气道高反应性。此外,DRA 暴露与气道上皮中 SPHK1 的表达增加有关,PF543 可减少这种表达。DRA 诱导的气道上皮中乙酰化 α-微管蛋白的减少与 NOTCH2 和 SPDEF 的表达增加有关,PF543 可预防这种增加。使用人原代气道上皮细胞的体外研究表明,使用 PF543 抑制 SPHK1 可防止过敏原诱导的 NOTCH2 和 SPDEF 均增加。SPHK1 的 siRNA 沉默可防止过敏原诱导的 NOTCH2 和 SPDEF 增加。在过敏原暴露时,NOTCH2 沉默与 SPDEF 的减少有关,但与 SPHK1 的减少无关。我们的研究表明,抑制 SPHK1 通过防止 GCM 和气道高反应性来保护过敏原挑战的气道,这与 NOTCH2-SPDEF 信号通路的下调有关。这表明 SPHK1、GCM 和哮喘气道重塑之间存在潜在的新联系。在过敏原诱导的小鼠模型中,已确立了鞘氨醇激酶 1 特异性抑制剂 PF543 预防杯状细胞化生(GCM)和气道高反应性(AHR)的作用。这种保护与 NOTCH2-SPDEF 信号通路的下调有关,表明 SPHK1、GCM 和 AHR 之间存在新的联系。